Remitting multiple sclerosis: Natalizumab reduces relapses and disability, review suggests
Tuesday, October 4, 2011 - 22:30
in Health & Medicine
Taking the new generation anti-inflammatory drug natalizumab for two years lowers the number of remitting multiple sclerosis patients who experience relapses and progression of disability.
